Sara Racine In Vitro Fertilization Unit, Lis Maternity Hospital, Tel Aviv, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Reprod Sci. 2021 Dec;28(12):3390-3396. doi: 10.1007/s43032-021-00622-2. Epub 2021 Jun 2.
The purpose of this research is to study the efficacy of GnRH-a versus r-hCG triggering in patients who go through fertility preservation cycles. This retrospective cohort study was performed in a tertiary university-affiliated medical center. It includes 191 patients undergoing fertility preservation cycles between May 2013 and September 2018, in which ovulation was induced by either GnRH-a or r-hCG. Main outcome measures were number and rate of mature oocyte. Among treatment cycles with medical indication, GnRH agonist significantly increases the odds for high mature rate by 3.55 (1.30-9.66), while in treatment cycles with social indication, there is no significant effect of the triggering agent. An advantage for GnRH-a triggering was observed in medically indicated preservation cycles.
本研究旨在探讨 GnRH-a 与 r-hCG 触发在接受生育保存周期的患者中的疗效。这是一项在三级大学附属医院进行的回顾性队列研究。该研究纳入了 2013 年 5 月至 2018 年 9 月期间接受生育保存周期的 191 例患者,这些患者通过 GnRH-a 或 r-hCG 诱导排卵。主要观察指标是成熟卵母细胞的数量和成熟率。在有医学指征的治疗周期中,促性腺激素释放激素激动剂显著增加了 3.55 倍(1.30-9.66)的高成熟率的可能性,而在有社会指征的治疗周期中,触发剂没有显著效果。在有医学指征的保存周期中,GnRH-a 触发有优势。